Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis

American Journal of Gastroenterology

Volumn 108, Issue 1, 2013, Pages 40-47

  Nanda, Kavinderjit S ^a   Cheifetz, Adam S ^a   Moss, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; UNCLASSIFIED DRUG;

CROHN DISEASE; DATA BASE; DATA EXTRACTION; ENTERITIS; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY; TREATMENT FAILURE;

EID: 84872050633     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.363     Document Type: Review

References (59)

1. Talley NJ, Abreu MT, Achkar JP et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106: S2-S25.
2. Clark M, Colombel JF, Feagan BC et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-39.
3. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-98.
4. Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-therapy. Aliment Pharmacol Ther 2011; 34: 1-10.
5. Rostholder E, Ahmed A, Cheifetz A et al. Outcomes aft er escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 562-7.
6. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
7. Regueiro M, Siemanowski B, Kip KE et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9.
8. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
9. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75.
10. Ben-Horin S, Yavzori M, Katz L et al. Th e immunogenic part of infliximab is the F (ab) 2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
11. Svenson M, Geborek P, Saxne T et al. Monitoring patients treated with anti-TNF-biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-34.
12. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
13. Farrell R, Alsahli M, Jeen Y et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
14. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to infliximab aft er maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
15. Vermeire S, Noman M, Van Assche G et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
16. Ainsworth M, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8.
17. Ben-Horin S, Mazor Y, Yanai H et al. Th e decline of anti-drug antibody titres aft er discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35: 714-22.
18. Steenholdt C, Al-khalaf M, Brynskov J et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012: Epub 29 August.
19. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012; 47: 136-43.
20. Pariente B, de Chambrun GP, Krzysiek R et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 18: 1199-206.
21. Maser EA, Villela R, Silverberg MS et al. Association of trough serum infliximab to clinical outcome aft er scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
22. Steenholdt C, Bendtzen K, Brynskov J et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
23. Seow CH, Newman A, Irwin SP et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
24. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008; 20: 431-5.
25. Rutgeerts P, Vermeire S, Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010; 59: 7-8.
26. Karmiris K, Paintaud G, Noman M et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
27. West R, Zelinkova Z, Wolbink G et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
28. Schreiber S, Khaliq-Kareemi M, Lawrance I et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-49.
29. Ahmed I, Kaspar B, Sharma U. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States. Clin Ther 2012; 34: 400-19.
30. Lahiff C, Kane S, Moss A. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis 2011; 17: 2585-93.
31. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
32. Guyatt G, Oxman A, Vist G et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011; 64: 407-15.
33. Stroup D, Berlin J, Morton S et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
35. Higgins JPT, Th ompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
36. Egger M, Smith GD, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
37. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2002; 2: 1-4.
38. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
39. Drastich P, Kozeluhova J, Jaresova M et al. Infliximab serum trough levels and deep remission in patients with IBD. Gastroenterology 2011; 140 (Suppl 1): S292.
40. Feagan BG, McDonald JW, Panaccione R et al. Methotrexate for the prevention of antibodies to infliximab in patients with Crohn's disease. Gastroenterology 2010; 138 (Suppl 1): S167-8.
41. Vermeire S, Gabriels F, Ballet V et al. Th e effect of dose escalation on trough levels in patients who lost response to infliximab. Gut 2010; 59: A81.
42. Afif W, Loft us EV, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
43. Van Moerkercke W, Ackaert C, Compernolle G et al. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology 2010; 138 (Suppl 1): S60.
44. Lichtenstein G, Diamond R, Wagner C et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD: subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
45. Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8.
46. Miele E, Markowitz JE, Mamula P et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38: 502-8.
47. Fasanmade A, Masters P, Munsanje E et al. Infliximab pharmacokinetics and improvement in fistulizing Crohn's disease. Gastroenterology 2003; 124 (Suppl 1): A61.
48. Settesoldi A, Giannotta M, Genise S et al. Loss of efficacy and adverse drug reactions during infliximab therapy in IBD patients are related to the appearance of anti-infliximab antibodies. Digestive Liver Dis 2012; 44 (Suppl 2): S194.
49. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
50. Yamada A, Sono K, Hosoe N et al. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16: 1898-04.
51. J ü rgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105: 1811-9.
52. Kopylov U, Mazor Y, Yavzori M et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18: 1628-33.
53. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Wiley Online Library, 2008.
54. Colombel J, Feagan B, Sandborn W et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 349-58.
55. Chaparro M, Guerra I, Mu ñ oz-Linares P et al. Systematic review: antibodies and anti-TNF-levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012: E-pub 22 March.
56. Sandler RS, Jordan MC, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol 1988; 41: 451-8.
57. Higgins J, Th ompson S, Deeks J et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7: 51-61.
58. Candon S, Mosca A, Ruemmele F et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006; 118: 11-9.
59. Arias MT, Drobne D, Vande Castelle N et al. Influence of trough serum levels and immunogenicity on long term outcome of infliximab therapy in ulcerative colitis. Gut 2011; 60: A.